GlaxoSmithKline has filed its shingles vaccine in Europe, as it seeks to boost sales with a new wave of drugs. The EU filing of Shingrix follows a US filing last month for the drug, which analysts ...

GSK (GSK) stock gains as the company's Q1 2025 results beat Street forecasts thanks to its Specialty Medicines business. Read ...

GSK stock jumped Wednesday after the British drugmaker said it's "well positioned" to respond if the U.S. levies tariffs on ...

GSK said it remains confident in its ability to absorb the financial impact of potential US pharmaceutical tariffs as it ...

GSK’s dealmaking will be “cautious and disciplined” under the current trade war, but the pharma will focus on looking for ...

As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the ...

A new study found shingles vaccination cut older adults’ risk of developing ... Another research group recently reported some evidence that it does. Vaccine manufacturer GSK last month announced a ...

GSK. She said some studies have found that other vaccines, including those against flu, create a generalized neuroprotective effect, but that because the shingles virus hides in nerves ...

Vaccine manufacturer GSK last month announced a collaboration ... shows a disposable syringe with hypodermic needle, SHINGLES written on a black board behind. (Photo Illustration by Frank ...

GlaxoSmithKline has filed its Shingrix shingles vaccine in the US, seeking approval for prevention of the disease in people aged 50 years or over. Shingrix has been touted as a potential ...